Provided by Tiger Fintech (Singapore) Pte. Ltd.

CureVac B.V.

3.16
+0.16005.33%
Pre-market: 3.210.0500+1.58%08:17 EST
Volume:756.94K
Turnover:2.37M
Market Cap:708.83M
PE:-2.37
High:3.18
Open:3.03
Low:3.03
Close:3.00
Loading ...

CureVac NV reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
14 Nov 2024

CureVac NV (CVAC) Q3 2024 Earnings Call Highlights: Strong Financial Performance and Strategic ...

GuruFocus.com
·
13 Nov 2024

CureVac Reports Surging Revenues and Profit Growth

TIPRANKS
·
13 Nov 2024

CureVac’s Financial Upsurge and Strategic Restructuring

TIPRANKS
·
13 Nov 2024

CureVac reports Q3 revenue EUR 493.9M vs. EUR 16.5M last year

TIPRANKS
·
12 Nov 2024

CureVac on track with 30% workforce reduction

TIPRANKS
·
12 Nov 2024

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

ACCESSWIRE
·
12 Nov 2024

CureVac Q3 Sales EUR493.90M Beat EUR103.76M Estimate; Represents 2,897% Increase From EUR 16.5M Prior Year

Benzinga
·
12 Nov 2024

CureVac NV expected to post earnings of 56 cents a share - Earnings Preview

Reuters
·
09 Nov 2024

CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024

ACCESSWIRE
·
07 Nov 2024

CureVac’s Latest mRNA Advances Spark Investor Interest

TIPRANKS
·
05 Nov 2024

CureVac Appoints New CFO to Drive Growth

TIPRANKS
·
05 Nov 2024

CureVac Appoints Axel Sven Malkomes as CFO

MT Newswires Live
·
05 Nov 2024

CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer

ACCESSWIRE
·
04 Nov 2024

CureVac: Names Sven Malkomes as CFO

THOMSON REUTERS
·
04 Nov 2024

CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

ACCESSWIRE
·
28 Oct 2024